Featured Stories

  • The COVID Heart - One Year After SARS-CoV-2 Infection, Patients Have an Array of Increased Cardiovascular Risks

    The COVID Heart - One Year After SARS-CoV-2 Infection, Patients Have an Array of Increased Cardiovascular Risks Published March 2, 2022: JAMA doi: 10.1001/jama.2022.2411

    Learn More

  • Long-term Cardiovascular Outcomes of COVID-19

    Long-term cardiovascular outcomes of COVID-19 Published Feb. 7, 2022: Nature Medecine  https://doi.org/10.1038/s41591-022-01689-3  

    Learn More

  • Understanding Pulmonary Arterial Hypertension Outcome Measures

    Pulmonary arterial hypertension (PAH) is a rare, life-threatening condition characterized by elevated blood pressure in the arteries which carry blood from the heart to the lungs. The high blood...

    Learn More

  • Calgary-based biotech firm specializes in instructing cells to fight complex diseases

    Imagine a world where a host of diseases and conditions caused by non-beneficial instructions from our DNA could be treated simply by instructing our cells to ignore those signals. That science is...

    Learn More

  • Health Matters: Alberta-developed drug could help prevent long COVID

    Health Matters February 2: Calgary company Resverlogix has developed a drug that could not only stop COVID-19 illness from progressing, it also has potential to prevent chronic symptoms, or long...

    Learn More

  • Calgary Company's COVID Drug Going to Phase Two Trials

    Calgary-based biotech company Resverlogix moves into a phase two clinical trial for an oral treatment Apabetalone for COVID-19. And they are looking for patients to participate in the study....

    Learn More

  • Made-in-Alberta drug being tested on COVID-19 patients

    New drug trial to treat COVID-19 patients has been launched at the University of Alberta. Hiba Kamal-Choufi reports.

    Learn More

  • 'Exciting breakthrough': COVID-19 drug trial to take place in Edmonton

    Trials for a Canadian-developed COVID-19 treatment are set to begin at the University of Alberta. CTV News Edmonton - Aired January 24, 2022

    Learn More

  • An Alberta-developed oral treatment for COVID-19 has begun testing at the University of Alberta hospital

    J'lyn Nye interviews RVX President & CEO Donald McCaffrey about our Phase 2b COVID-19 Clinical Trial on 630 CHED

    Learn More

  • Some COVID-19 patients in Edmonton begin potential trial treatment, apabetalone, an Alberta-developed drug

    By Kellen Taniguchi Edmonton Journal, January 18, 2022  

    Learn More

  • Epigenetic Therapies Start Operating Outside the Lines

    Drug developers are sourcing novel structures, bridging transcriptional and signaling domains, and exploring applications beyond oncology GEN: Genetic Engineering and Biotechnology News...

    Learn More

  • Resverlogix in Active Discussions with Morocco

    Resverlogix is in active discussions for COVID-19 clinical studies in Morocco involving apabetalone.

    Learn More

  • Donald McCaffrey at Benzinga All Access

    Resverlogix President & CEO Donald McCaffrey presents at Benzinga All Access conference 2021

    Learn More

  • Resverlogix: The Future of Drug Development

    Clip of Donald McCaffrey, President & CEO of Resverlogix which aired on Fox News December 18, 2021.   © 2021 www.B-TV.com . All Rights Reserved.  

    Learn More

  • Apabetalone meets primary endpoint in PAH pilot study

    Resverlogix reported that its lead drug apabetalone met its primary endpoint in a pulmonary arterial hypertension or ‘PAH’ investigator led pilot study. Watch the news...

    Learn More

  • EVERSANA & Resverlogix Discuss Partnership On PharmaVOICE Webinar

    Rohit Sood, EVP, COMPLETE Commercialization, EVERSANA / Donald McCaffrey, President & CEO, Resverlogix: Next Generation Commercial Innovation: Moving From Promise to Practice. 

    Learn More

  • Donald McCaffrey featured on Innovators with Jane King

    Donald McCaffrey, President & CEO of Resverlogix featured on Innovators with Jane King. Latest updates on the Company's COVID-19 program.

    Learn More

  • COVID-19 Program Update with Donald McCaffrey

    CEO Donald McCaffrey joined PBA à Noon, for a live webinar and Q&A, to discuss the latest developments in Resverlogix' COVID-19 program.

    Learn More

  • Health Canada Authorizes COVID-19 Clinical Study

    Resverlogix receives "No Objection Letter" from Health Canada, approving the COVID-19 Clinical Trial Application for apabetalone.

    Learn More

  • Apabetalone May Prevent Heart Damage Caused by COVID-19

    COVID-19 affects not only lung and respiratory tissue but can injure your heart as well. One study, published in the Journal of the American Medical Association, found that 78% of recently...

    Learn More

  • Balancing Epigenetics in the Treatment of Chronic Kidney Disease

    Kidneys are the body’s filtration system . They clean our blood, removing waste and helping manage blood pressure by controlling the outflow of water. Unfortunately, when these filters...

    Learn More

  • Targeting Epigenetics as a New Therapy in Vascular Disease and Dementia

    Cardiovascular disease literally means disease of the heart and blood vessels, but it can cause additional life-altering complications that we might not initially associate with the disease,...

    Learn More

  • The Faces of Cardiovascular Disease: Series Final

    This is the final article of the mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men...

    Learn More

  • The Faces of Cardiovascular Disease: Part 4

    This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...

    Learn More

  • The Faces of Cardiovascular Disease: Part 3

    This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...

    Learn More

  • The Faces of Cardiovascular Disease: Part 2

    This article is part of a mini-series, The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of men and women...

    Learn More

  • The Faces of Cardiovascular Disease: Part 1

    This article is part of a mini-series we are calling The Faces of Cardiovascular Disease , looking at the different presentations, symptoms, and root causes of a disease that affects millions of...

    Learn More

  • Apabetalone: A Relative Size Animation

    Our lead compound – apabetalone – is the first small molecule of its kind with potentially important benefits for patients with high-risk cardiovascular and other chronic diseases. But...

    Learn More